Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.

Therapeutic advances in medical oncology·2026
Same author

EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.

bioRxiv : the preprint server for biology·2026
Same author

Mental Health Needs of Families of Patients in Intensive Care Units and the Role of Mobile Health: Survey Study.

JMIR formative research·2026
Same author

Investigating the Feasibility, Usability, and Efficacy of a Mobile App to Reduce Anxiety and Depression in Families of Critical Care Cancer Patients: A Quasi-Experimental Pilot Study.

Healthcare (Basel, Switzerland)·2026
Same author

Anti-AMPAR limbic encephalitis as the initial presentation of metastatic small cell cancer.

BMJ case reports·2026
Same author

Uncovering Hidden Marginalized Populations in Lung Cancer Screening via Latent Class Analysis.

Mayo Clinic proceedings·2025

Related Experiment Video

Updated: Jul 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.

Lauren S Yeager1, Ralph G Zinner1, Zhonglin Hao1

  • 1Division of Medical Oncology, University of Kentucky Markey Cancer Center, Lexington, USA.

Cureus
|July 6, 2026
PubMed
Summary

Pembrolizumab can cause asymptomatic hypertriglyceridemia, a rare immune-related adverse event. Routine monitoring is crucial for patients receiving pembrolizumab (an immune checkpoint inhibitor) to detect and manage such side effects early.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Pembrolizumab, an immune checkpoint inhibitor, treats various cancers but can cause immune-related adverse events.
Keywords:
asymptomatic hypertriglyceridemiaimmunotherapy hypertriglyceridemiaimmunotherapy-related adverse eventsmetastatic non-small cell lung cancerpembrolizumab toxicitypembrolizumab-associated hypertriglyceridemiarare immunotherapy adverse event

Related Experiment Videos

Last Updated: Jul 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

  • Management guidelines exist for symptomatic hypertriglyceridemia, but not for asymptomatic cases.
  • Asymptomatic hypertriglyceridemia is a rare, underreported adverse event associated with pembrolizumab therapy.